RAPT
$30.06
Rapt Therapeutics
($2.15)
(6.67%)
RAPT
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.64)
Revenue:  $1.90 Mil
Wednesday
Feb 9
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when RAPT reports earnings?
Beat
Meet
Miss

Where is RAPT's stock price going from here?
Up
Flat
Down
Stock chart of RAPT
Analysts
Summary of analysts' recommendations for RAPT
Score
Grade
Pivots
Resistance
$35.17
$33.95
$32.00

$30.78

Support
$28.83
$27.61
$25.66
Tweet
Growth
Description
RAPT Therapeutics Inc. is a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193, a CCR4 antagonist for allergic inflammatory disease. RAPT Therapeutics Inc. is based in San Francisco, California.